Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT04516447 is registered in ClinicalTrials.gov with K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc as lead sponsor.

NCT NCT04516447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04516447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
October 26, 2020
Completion date
June 30, 2028
Enrollment
172 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, solid tumor